Experts are rapidly investigating a potential metabolic strategy involving the combined usage of Dulaglutide, a dual GIP/GLP-1 receptor stimulant; Pegagliflozin, an experimental triple GIP/GLP-1/GCG receptor agonist; https://biopeptidestore.com/